CBX

 Chia Tai-Tianqing (CTTQ) has initiated a clinical study ( NCT06218771 ) of TQB3454, an IDH1 inhibitor, in patients with AML/MDS. This trial started in July 2023, while the study of IDH2 inhibitor TQB3455 was terminated in 2021 due to slow enrollment . IDH mutations for cancer The first Investigational New Drug (IND) application for TQB3454 was filed for the treatment of solid tumors and blood cancers in China in 2020. The first-in-human clinical trial was initiated in August of that year enrolling patients with advanced solid tumors or hematologic malignancies. While no results from this initial trial have been publicly reported, several other clinical trials for TQB3454 are currently ongoing and recruiting participants. In 2023, CTTQ initiated a phase 1 clinical study ( NCT05987358 ) of TQB3454 in patients with  advanced biliary carcinoma , with an estimated enrollment of 165 participants. IDH1 mutations occur in approximately 13% of patients with intrahepatic cholangiocarcinoma. A

 Due to the pharmaceutical industry's cold spell, an increasing number of enterprises are facing insufficient cash flow to support a multitude of clinical trials. Consequently, there is a rising trend of termination of clinical trials. It is well-known that the collaboration between CTTQ and Wuxi Apptec is very close.  Here we summarize the clinical trials terminated or suspended by Chia Tai-Tianqing: 1.  TQB3015 for cancer: ATR inhibitor CTR20233919: phase 1 trial suspended without explanation Initiated in 2023.12.05, suspended in 2023.12.19 2. TQC3564 for asthma: CRTH2 antagonist CTR20220230: phase 1b study terminated as strategy adjustment Initiated in 2022.1.29, terminated in 2023.5.9 3.  TQC3564  for allergic rhinitis :  CRTH2  antagonist CTR20220964: phase 1b study terminated as strategy adjustment Initiated in 2022.8.17, terminated in 2023.5.9 4.  TQB3823 for cancer: PARP  inhibitor CTR20211789: phase 1 trial terminated as strategy adjustment Initiated in 2021.9.14, termin